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Abstract 
The standard treatment in the early stage of
maxillary  sinus  cancer  is  surgical  resection
followed  by  postoperative  radiation  therapy.
However, for locally advanced maxillary sinus
cancer, a multimodality treatment approach is
strongly recommended to improve the survival
rate and quality of life of the patient. We deter-
mined  the  treatment  outcomes  of  induction
chemotherapy,  concurrent  chemoradiation
therapy,  and  surgical  resection  for  locally
advanced  maxillary  sinus  cancer.  Forty-four
patients with locally advanced maxillary sinus
cancer, who had been treated between January
1990  and  April  2008  at  Kangnam  St.  Mary's
Hospital,  were  retrospectively  analyzed.  The
objective response rates were 70%, 53%, and
57% in the intra-arterial induction chemother-
apy, intravenous induction chemotherapy, and
concurrent  chemoradiation  therapy  groups,
respectively.  The  orbital  preservation  rates
were 83%, 100%, and 75% in the intra-arterial
induction  chemotherapy,  intravenous  induc-
tion  chemotherapy,  and  surgical  resection
groups, respectively. In seven of nine patients
in  whom  the  orbit  could  be  preserved  after
induction chemotherapy, the primary tumors
were removed completely. However, although
the  orbits  were  preserved  in  three  patients
who underwent surgical resection as a primary
treatment, all three cases were confirmed to be
incomplete  resections.  We  found  that  active
induction  chemotherapy  for  locally  advanced
cancer  of  the  maxillary  sinus  increased  the
possibility of complete resection with orbital
preservation as well as tumor down-staging. 
Introduction
Malignant tumors of the maxillary sinus are
rare neoplasms that account for approximately
3% of head and neck cancers and 0.5% of all
malignant diseases. The annual incidence of
maxillary  sinus  cancer  is  0.5-1.0  case  per
100,000 of the population.
1 Squamous cell car-
cinoma is the most common histologic type,
accounting  for  approximately  70-80%  of  the
cancers. The other histologic types of maxillary
sinus cancer include adenoid cystic carcino-
mas, adenocarcinomas, mucoepidermoid car-
cinomas, sarcomas, and lymphomas. Smoking
and histories of chronic sinusitis are the most
common risk factors for maxillary sinus can-
cer.  In  addition,  occupational  exposure  to
chemical  substances,  such  as  formaldehyde,
chromium, nickel, and air pollution is associat-
ed with an increased risk for malignant tumors
of the maxillary sinus.
2
Most patients with maxillary sinus cancer
have  no  symptoms  in  the  early  stage  and,
therefore,  many  of  these  patients  are  diag-
nosed in the advanced stage of the disease.
The complexity of the anatomy and the proxim-
ity of the eyes, brain, and cranial nerves render
complete  surgical  resection  difficult,  which
leads  to  local  recurrence,  a  major  cause  of
treatment failure.
3 The other issues pertaining
to maxillary sinus cancer include the function-
al aspects of eyesight and the cosmetic aspects
of facial contours, which make patients avoid
surgical resection. 
The standard treatment for maxillary sinus
cancer  has  been  surgical  resection  with  or
without orbital exenteration, followed by post-
operative  radiation  therapy.  However,  in  the
advanced  stages,  tumor  control  and  survival
rate are still considered to be unsatisfactory,
with a local control rate of 50-60% and a five-
year disease-specific survival rate of 30-50%.
3,4
Since the late 1970s, multimodality treatments
have  been  investigated  for  the  treatment  of
locally advanced maxillary sinus cancer, with
the purpose of improvement in tumor control
rate and reduction of functional impairment.
Notably,  induction  chemotherapy  (ICT)  and
concurrent  chemoradiation  therapy  (CCRT)
are  the  most  common  multimodality  treat-
ments for stages III and IV locally advanced
maxillary  sinus  cancer.  We  investigated  the
treatment outcomes including orbital preser-
vation,  complete  resection,  pathologic  down-
staging, and relapse patterns in patients with
locally advanced maxillary sinus cancer who
underwent ICT, CCRT, and surgical resection. 
Materials and Methods
Patients
Seventy-five  patients  who  had  been  diag-
nosed with maxillary sinus cancer at Kangnam
St.  Mary's  Hospital  between  1  January  1990
and 30 April 2008 were reviewed. Among these
patients, 10 received only palliative care owing
to poor performance status, and seven patients
with a history of prior surgery or chemothera-
py  were  excluded.  In  addition,  fourteen
patients with malignant lymphomas or soft tis-
sue  sarcomas  were  excluded.  Finally,  44
patients were analyzed and reviewed on the
basis of their medical records, pathology slides
and interpretation reports, and imaging stud-
ies.  The  following  data  were  collected:  age,
gender,  performance  status,  histopathologic
diagnosis,  tumor  staging,  orbital  invasion,
treatment  modalities,  recurrences,  and  sur-
vival rates.
A detailed assessment of the tumor extent
was  performed  in  all  patients,  based  on  CT
scans and/or MRI including the maxillary sinus
and skull base. The orbital invasion was deter-
mined on these findings: contact of the mass
with the lamina papyracea, erosion or destruc-
tion of the medial and/or inferior orbital wall,
and  invasion  of  the  periorbital  soft  tissue
including  the  optic  nerves  and  extraocular
muscles. Tumor staging was done using the
2006 edition of the American Joint Committee
on  Cancer  (AJCC)  classification,  and  retro-
spective restaging was done in previously diag-
nosed patients. The performance status was
evaluated  according  to  Eastern  Cooperative
Oncology Group (ECOG) criteria. 
Chemotherapy
One of four different treatment modalities,
including  intra-arterial  (IA)-ICT,  intravenous
(IV)-ICT,  CCRT,  and  surgical  resection,  was
selected as a primary treatment based on the
TNM stage, performance status, age, and co-
morbidity. ICT was administered through the
IA or IV route. Superselective IA infusion of
chemotherapeutic drugs was attempted via a
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series  of  processes.  The  contrast-enhanced
tumor mass and tumor feeding vessels were
confirmed via diagnostic angiographic proce-
dures  of  the  internal  and  external  carotid
arteries by means of transfemoral access. The
internal  maxillary  artery  was  superselected
with a microcatheter, and then the chemother-
apeutic  drug  was  administered  via  a  micro-
catheter into the tumor-supplying artery. The
transfemoral catheter was removed on comple-
tion of the infusion. Cisplatin (100 mg/m
2) was
administered  via  a  microcatheter  into  the
internal maxillary artery over two hours on day
1, and then 5-FU (1000 mg/m
2/day) was contin-
uously infused from day 1 to day 5 over 120
hours through the IV route. A standard hydra-
tion  and  mannitol  diuresis  regimen  were
applied. The entire procedure was repeated 2-
3 times every 3-4 weeks. 
The IV-ICT was performed 2-3 times every
four weeks as well. Cisplatin (100 mg/m
2) was
administered intravenously over two hours on
day 1, and 5-FU (1000 mg/m
2/day) was infused
continuously  from  day  1  to  day  5  over  120
hours through the IV route. All patients who
received  ICT  were  re-evaluated  for  tumor
response  with  CT  and/or  MRI  at  least  4-6
weeks after the completion of ICT. The deci-
sion to perform surgery after ICT was based on
the tumor response. 
The  chemotherapeutic  agent  used  in  the
CCRT  group  was  cisplatin.  During  radiation
therapy,  cisplatin  (30  mg/m
2)  was  adminis-
tered by a weekly schedule on days 1, 8, 15, 22,
29, 36, 43, and 50, or cisplatin (100 mg/m
2) was
administered every 3 weeks on days 1, 22, and
43.  All  patients  treated  with  CCRT  were  re-
evaluated  for  tumor  response,  and  then  the
next treatment modality, surgical resection or
salvage  chemotherapy,  was  determined.  The
periodic follow-up was done at least 6-8 weeks
after the completion of radiation therapy.
Surgical resection and radiation
therapy
In most cases, a total maxillectomy with orbital
preservation  was  carried  out.  However,  if  the
tumor mass extended to the lamina papyracea
and invaded the orbit and muscles, an orbital
exenteration with a total maxillectomy should be
performed. The patients with metastatic cervical
lymphadenopathy underwent a modified radical
neck  dissection.  Three-dimensional  conformal
radiation therapy (3DCRT) was applied as an
external radiation therapy technique. The total
dose of 55-60 Gy with 1.8-2.0 Gy daily fractions
five times per week was given to the clinical tar-
get volume (CTV) in postoperative adjuvant radi-
ation therapy. In the case of CCRT, the total dose
of 70-75 Gy in 35-40 fractions was given with a
shrinking-field technique; 50 Gy was given to the
CTV with daily fractions of 1.8 Gy five times per
week,  and  followed  by  20-25  Gy  to  the  gross
tumor volume (GTV).
Evaluation of treatment outcomes
The primary end point of our study was the
response rate of the primary treatment modal-
ities (IA-ICT, IV-ICT, and CCRT). For the evalu-
ation of tumor response, a physical examina-
tion, nasal endoscopy, and CT or MRI were per-
formed. Tumor response was assessed accord-
ing to the RECIST criteria (version 1.0). An
objective tumor response was defined as more
than partial response (PR). When recurrence
or distant metastasis was suspected, PET-CT
and  other  imaging  studies  of  suspicious
lesions were performed and, if needed, con-
firmed by biopsy. 
The secondary end points were the complete
resection  and  orbital  preservation  rates  in
patients  who  underwent  surgical  resection
after ICT and surgical resection as a primary
treatment. Complete resection was defined as
where  there  were  no  microscopic  residual
tumor  cells  on  the  resection  margin,  and
incomplete  resection  was  defined  as  where
there were residual tumors on the resection
margin, identified by gross and/or microscopic
examination. Orbital preservation was defined
as when a case underwent total maxillectomy
without  orbital  exenteration,  among  the
patients with the evidence of orbital invasion
on physical examinations and/or imaging stud-
ies at the time of diagnosis. 
The tertiary end points were overall survival,
recurrence  rate,  and  the  toxicity  profile.
Overall survival was defined as from the date
of diagnosis to the date of death or date of last
follow-up. The adverse events occurring during
ICT and CCRT were graded according to the
National  Cancer  Institute  Common  Toxicity
Criteria (NCI-CTC, version 2.0).
Statistical analysis 
For  categorical  outcomes,  between-group
comparisons  were  done  using  either  the
Fisher’s exact test or a Chi-square test. The
overall survival curve was estimated using the
Kaplan-Meier  method,  and  the  log-rank  test
was applied to assess statistical significance.
All statistical analyses were performed using
the SPSS program (version 13.0) and a p value
of <0.05 was considered as statistically signif-
icant.
Results
Patient characteristics
The  clinical  characteristics  of  the  44
patients are summarized in Table 1. The medi-
an age was 60 years (range 33-89 years) and
93% of patients were ECOG 0-1. The most com-
mon  histopathologic  subtype  was  squamous
cell  carcinoma  (n=31;  70%).  Of  the  44
patients, 12 patients (27%) underwent surgi-
cal  resection  as  a  primary  treatment,  and
among  these  patients  there  were  six  (50%)
with stage III, five (42%) with stage IV, and one
Article
Table 1. Patient characteristics.
Patient characteristics (n=44) n (%)
Gender (male/ female) 30(68)/14(32)
Median age (years, range) 60(33-89)
ECOG performance
0/1/2 17(39)/24(54)/3(7)
Histologic type
Squamous cell carcinoma 31(70)
Adenoid cystic carcinoma 6(14)
Adenocarcinoma 4(9)
Myoepithelial carcinoma 1(2)
Undifferentiated carcinoma 2(5)
TNM stage
II/III/IVa/IVb 1(2)/10(23)/10(23)/23(52)
Tstage
T2/T3/T4a/T4b 1(2)/10(23)/10(23)/23(52)
Nstage
N0/N1/N2 36(81)/5(11)/3(8)
Orbit invasion
yes/ no 31(70)/13(30)
Treatment modalities
†IA-ICT/
‡IV-ICT 10(23)/15(34)
§CCRT/Surgical resection 7(16)/12(27)
†IA-ICT: intra-arterial induction chemotherapy, 
‡IV-ICT: intravenous induction chemotherapy, 
§CCRT:
concurrent chemoradiation therapy.[page 112] [Rare Tumors 2009; 1:e36]
(8%)  with  stage  II  tumors.  Eleven  patients
with stage III-IV tumors received postoperative
adjuvant radiation therapy after surgical resec-
tion.  Ten  (23%),  15  (34%),  and  7  (16%)
patients  received  IA-ICT,  IV-ICT,  and  CCRT,
respectively. Of the 25 patients who received
ICT, there were 21 (84%) with stage IV and 3
(16%) with stage III tumors. All patients treat-
ed with CCRT were stage IV. The median dura-
tion of follow-up was 16 months.  
Tumor response and toxicity
The  objective  response  rates  of  ICT  and
CCRT  were  60%  and  57%,  respectively
(p=0.521). The objective response rates of IA-
ICT and IV-ICT were 70% and 53%, respective-
ly (p=0.311) (Table 2). In the 10 patients who
received  IA-ICT,  no  complete  response  (CR)
was achieved, seven patients (70%) had a PR,
one patient had stable disease (SD), and one
patient  had  progressive  disease  (PD).  The
intended chemotherapy was interrupted in one
patient because of acute, severe toxicity. In the
15 patients treated with IV-ICT, two (13%) had
a CR, six (40%) had a PR, three (20%) had SD,
and three (20%) had PD. One patient was lost
to follow-up. The most common acute toxicity
associated  with  these  treatment  modalities
was  nausea  and  vomiting.  The  frequency  of
nausea and vomiting in the IA-ICT, IV-ICT, and
CCRT groups was 70%, 87%, and 86%, respec-
tively (p=0.927). The patients treated with IA-
ICT experienced other adverse events: three
patients had facial swelling, three had perior-
bital pain, one had severe mucositis, and one
had transient dizziness.
Orbital preservation and complete
resection rate
Seven (70%) of 10 patients in the IA-ICT
group and seven (47%) of 15 patients in the IV-
ICT group underwent surgical resection with
curative  intent.  Of  these  patients,  those  in
whom orbital invasion had been confirmed by
imaging studies at diagnosis were six and four
patients  in  the  IA-ICT  and  IV-ICT  groups,
respectively. Orbital preservation was possible
in five (83%) of six patients treated with IA-
ICT  and  in  all  four  (100%)  patients  treated
with IV-ICT. On the other hand, orbital inva-
sion was doubtful in four of 12 patients who
underwent  surgical  resection  as  a  primary
treatment, and orbital preservation was possi-
ble in three (75%) of four patients. Therefore,
there were no statistically significant differ-
ences in the orbital preservation rates between
the  ICT  and  surgical  resection  groups
(p=0.505). Seven (78%) of nine patients with
orbit preservation in the ICT group had com-
plete  resections.  However,  all  three  patients
with orbital preservation in the primary surgi-
cal resection group had incomplete resections.
Therefore,  a  higher  complete  resection  rate
was achieved in the patients who underwent
surgical resection after ICT (Figure 1). 
Pathologic down-staging by ICT
Of the 14 patients who underwent ICT fol-
lowed  by  surgical  resection,  the  10  patients
with T4 tumors were available for pathologic
tumor  response.  Nine  (90%)  of  10  patients
were shown to have pathologic down-staging
of the primary tumor after ICT. Among the 10
patients with clinical T4, five had pT3, three
had pT1, and one had a pathologic CR (pT0).
All cases with remarkable down-staging to pT1
and pT0 were observed in the IA-ICT group. 
Overall survival and recurrence rate
The overall survival curve of the 44 patients
is shown in Figure 2. The overall survival rate
for these 44 patients was 60% at three years
and 53% at five years. 
The three-year survival rate was 57% and
50% in the IA-ICT and IV-ICT group, respective-
ly (p=0.665). The most common cause of death
was disease progression. Two of 10 patients in
the IA-ICT group died; one patient owing to
disease  progression  and  the  other  patient
because  of  infectious  disease  after  relapse
with lung metastasis. Five of 15 patients in the
IV-ICT group died; three as a result of disease
Article
Table 2. Tumor response according to treatment modalities.
Treatment modalities Tumor response  p
†CR(n)
‡PR(n)
§ORR(%)
Induction chemotherapy 60 0.521
IA-ICT 0770 0.311
IV-ICT 2653
CCRT 1357
†CR: complete response, 
‡PR: partial response, 
§ORR: overall response rate.
Figure  1.  Orbital  preserva-
tion  and  complete  resection
rate  according  to  treatment
modalities.  IA-ICT:  intra-
arterial  induction
chemotherapy, IV-ICT: intra-
venous induction chemother-
apy.
Figure  2.  Overall  survival
curve  of  44  patients  with
maxillary sinus malignancies
by  the  Kaplan-Meier
method.
Article
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progression and two owing to infectious dis-
ease accompanied by disease progression. Of
the 12 patients in the surgical resection group,
eight  were  still  alive  without  recurrence  for
more than two years, but three of four patients
with recurrences died of disease progression
and one person was lost to follow-up. 
The recurrence patterns were as follows: in
seven patients who received IA-ICT followed by
surgical resection, no local recurrences were
identified except for one pulmonary metasta-
sis. In nine patients who received IV-ICT fol-
lowed by surgical resection, three local recur-
rences  and  two  distant  metastases  were
detected during the follow-up period. Hence,
the recurrence rates were 17% and 56% in the
IA-ICT and IV-ICT group, respectively. In the
surgical  resection  group,  local  recurrences
occurred in four (33%) of 12 patients.  
In the ICT group, two patients with a posi-
tive resection margin died of local recurrence
within  two  years.  In  contrast,  one  of  seven
patients  with  a  tumor-free  resection  margin
died of local recurrence, and the six remaining
patients  with  squamous  cell  carcinoma  had
long-term disease-free survival. In the surgical
resection group, one of three patients with a
positive resection margin died of a local recur-
rence,  and  the  remaining  two  patients  with
adenoid cystic carcinoma are alive still. Most
recurrences occurred within the first two years
after  surgical  resection  or  complete  clinical
response to ICT, and those who had no recur-
rences within the first two years had a long-
term survival of more than five years. 
Discussion
The prognosis of maxillary sinus cancer is
disappointing, despite aggressive treatments.
For successful treatment outcomes, it is neces-
sary to acquire complete surgical resection and
to secure adequate resection margins.
However, maxillary sinus cancers usually are
diagnosed at advanced stages, and the proximi-
ty of important organs such as the eyes and cra-
nial nerves makes complete surgical resection
difficult.  In  addition,  functional  impairments
after surgical resection are the major cause of a
decreased  quality  of  life.  Therefore,  surgical
resection with a curative intent should be con-
sidered as a primary treatment only in the early
stages of the disease. In the advanced stages,
multimodality  treatment  strategies  should  be
arranged  for  prolongation  of  survival  and
improvement in the quality of life. 
CCRT  is  regarded  as  the  more  effective
treatment because of the radiosensitizing effi-
cacy of cisplatin compared with radiation ther-
apy alone. Several studies have demonstrated
that CCRT has a higher tumor control rate and
survival rate in head and neck cancers than
radiation therapy alone.
5 Harrison et al. report-
ed a three-year local control rate of 78% and a
three-year survival rate of 42% in 12 patients
with paranasal sinus carcinomas treated with
cisplatin-based  CCRT.
6 In  this  study,  seven
patients with stage IV maxillary sinus cancer
received CCRT as a primary treatment, and the
objective response rate was 57%. However, the
assessments of recurrence and survival rate
were impossible because of small sample size
and loss to follow-up. 
The  most  commonly  used  ICT  in  locally
advanced head and neck cancer is IV cisplatin
combined with a 5-FU continuous infusion. In
several  studies,  ICT  produced  an  objective
response rate of 60-90% with a clinical CR of
20-50%.
5 However,  the  antitumor  efficacy  of
ICT did not lead to a prolongation in overall
survival in every case. 
To improve the antitumor efficacy, the addi-
tion of potent cytotoxic drugs such as docetax-
el  to  a  standard  chemotherapy  regimen  or
development of new drug delivery methods has
been investigated actively. As one of the drug
delivery methods, a superselective IA infusion
of chemotherapeutic drugs has been proposed
as an ICT in locally advanced head and neck
cancers. Direct infusion of chemotherapeutic
drugs to the feeding vessels exposed a high
concentration of drug to the tumor cells; there-
fore,  more  potent  antitumor  efficacy  with
lower  systemic  toxicity  was  expected.
7 IA
chemotherapy may be more effective when it is
administered as an initial treatment. Because
prior  surgery  or  radiation  impairs  the  blood
supply to the tumor bed, it makes local delivery
of chemotherapeutic drugs difficult. Although
the  majority  of  head  and  neck  cancers  are
diagnosed at advanced stages of the disease,
distant metastases are rarely detected at the
time  of  presentation.  Moreover,  maxillary
sinus cancers are confined to the territory of
the terminal branch of the internal maxillary
artery; therefore, they are suitable for the local
infusion of chemotherapeutic drugs.
8,9
Robbins et al. reported a higher objective
response rate of 92%, with a CR of 88% in 76
patients with head and neck cancers treated
with  IA  cisplatin  and  concomitant  radiation
therapy.
10 In another study, a five-year survival
rate of 53% was reported, with a local recur-
rence rate of 15% in 19 patients with locally
advanced paranasal sinus cancers who under-
went surgical resection after IA chemotherapy
combined with concomitant radiation therapy.
Orbital preservation was possible in three of
four patients with orbital invasion.
4 Lee et al.
presented  their  clinical  experiences  with
superselective IA cisplatin combined with IV 5-
FU  in  advanced  paranasal  sinus  cancers.
11
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Figure 3. A case of a T4b maxillary sinus
cancer patient with: (A) magnetic reso-
nance imaging at diagnosis; (B) magnet-
ic  resonance  imaging  after  completion
of three cycles of intra-arterial induction
chemotherapy with cisplatin and intra-
venous  5-FU;  (C)  magnetic  resonance
imaging six months after total maxillec-
tomy with flap reconstruction.
A
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Forty-three  percent  of  21  evaluated  patients
had a CR and 48% of the patients had a PR,
with an objective response rate of 91%. In our
study, either IA-ICT or IV-ICT was performed as
an ICT. The objective response rate in the IA-
ICT group was 70%, which was similar to pre-
vious results, and the objective response rate
in the IV-ICT group was 53%. There were no
statistically  significant  differences  in  the
response rate and toxicities between the two
groups. 
The  orbital  preservation  rates  in  the
patients  with  paranasal  sinus  tumors,  who
received the ICT followed by surgical resection
or  CCRT,  have  been  reported  to  be  approxi-
mately 50-70%.
12,13 In this study, orbital preser-
vation was possible in five of six patients in
the IA-ICT group and all four patients in the IV-
ICT group. Although orbital preservation was
possible in three of four patients who under-
went  surgical  resection  as  a  primary  treat-
ment,  incomplete  resection  with  a  positive
resection  margin  was  finally  ascertained  in
these  three  patients.  On  the  other  hand,  in
nine patients who underwent ICT followed by
surgical  resection  with  orbit  preservation,
incomplete  resection  was  confirmed  in  only
two patients. Most of the patients with a posi-
tive  resection  margin  experienced  a  local
recurrence during the follow-up, which led to a
disease progression and then death.
A  case  of  a  patient  with  locally  advanced
maxillary sinus cancer is shown in Figure 3.
This patient was diagnosed with T4b maxillary
sinus  cancer  with  orbital  invasion  in  May
2007. She received three cycles of IA-ICT with
cisplatin  and  IV  5-FU,  and  then  underwent
total  maxillectomy  with  orbital  preservation
and  flap  reconstruction.  On  the  pathologic
reports, the tumor was removed nearly com-
pletely  but  close  to  a  margin.  She  received
postoperative  radiation  therapy.  She  has
remained disease free to date.
Several  studies  have  demonstrated  that  a
pathologic CR has a closer relationship than a
clinical CR with survival.
14 In the current study,
the  pathologic  down-staging  of  the  primary
tumor in the patients treated with ICT followed
by  surgical  resection  was  evaluated.  In  10
cases of T4 tumors, pathologic down-staging
after the ICT was identified in nine cases with
one  pathologic  CR.  In  addition,  IA-ICT  was
more  effective  with  respect  to  pathologic
tumor down-staging compared with IV-ICT. It is
thought that the first-passage effect and expo-
sure to higher local concentrations during IA
cisplatin have a major role in effective down-
staging.
15,16 There were no statistically signifi-
cant differences in survival rate between the
IA-ICT and IV-ICT groups. However, the local
recurrence rate was lower in the IA-ICT group
than in the IV-ICT group. 
The limitation of this study is that it is a ret-
rospective, relatively small sample size evalua-
tion.  Additionally,  a  discrepancy  in  clinical
characteristics  between  groups  existed.
Patients  diagnosed  with  a  more  advanced
staged tumor or orbital invasions were more
likely to receive ICT than surgery; therefore,
comparing  survival  according  to  treatment
modalities  was  difficult.  However,  clinical
characteristics between the IA-ICT and IV-ICT
groups were comparable and the comparison
of these two groups may bear significance.
Conclusion
From  our  study  we  conclude  that  ICT  in
locally  advanced  maxillary  sinus  cancers
increased the possibility of tumor down-stag-
ing and complete resection with orbital preser-
vation. Although there were no significant dif-
ferences in response rate and toxicity profile
between  the  two  groups  of  ICT,  IA-ICT  was
superior to IV-ICT with respect to tumor down-
staging and local tumor control. In the future,
a large-sized, prospective randomized study to
compare  ICT  followed  by  surgical  resection
with surgical resection alone is warranted clin-
ically  as  a  primary  treatment  for  locally
advanced maxillary sinus cancers. 
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